Vous êtes ici : Accueil / Valorisation / Publications / 2020

Infos pratiques

Organigramme
Contacts
  • Directeur :

        Pr Eric DELAPORTE

  • Directeur Adjoint :

        Bernard TAVERNE

Accès à la Délégation Régionale IRD-Occitanie (Montpellier)

2020

Tram J., Le Baccon-Sollier P., Bolloré K., Ducos J., Mondain A.-M., Pastor P., Pageaux G.-P., Makinson A., Van de Perre P., et Tuaillon E.,
RNA testing for the diagnosis of acute hepatitis A during the 2017 outbreak in France,
J. Viral Hepat., janv. 2020. doi: 10.1111/jvh.13255.

Barraud O., Robert A., Laval L., Ruimy R., Morquin D., Boyer L., et Lamy B.,
It takes two to tango: two Aeromonas isolates combine virulence and multidrug resistance in flap infection following leech therapy,
Clin. Microbiol. Infect., janv. 2020. doi: 10.1016/j.cmi.2019.12.021.

Liégeois F., Boyer S., Eymard-Duvernay S., Carrieri P., Kouanfack C., Domyeum J., Maradan G., Ducos J., Mpoudi-Ngolé E., Spire B., Delaporte E., Kuaban C., Vidal L., Laurent C., et EVOLCAM study group,
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM),
BMC Infect. Dis., vol. 20, no 1, p. 49, janv. 2020. doi: 10.1186/s12879-020-4784-7.

Poizot-Martin I., Obry-Roguet V., Duvivier C., Lions C., Huleux T., Jacomet C., Ferry T., Cheret A., Allavena C., Bani-Sadr F., Palich R., Cabié A., Fresard A., Pugliese P., Delobel P., Lamaury I., Hustache-Mathieu L., Brégigeon S., Makinson A., Rey D., et Dat’AIDS study group,
Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015,
J Eur Acad Dermatol Venereol, janv. 2020. doi: 10.1111/jdv.16204.

Navarro M., Camprubí D., Requena-Méndez A., Buonfrate D., Giorli G., Kamgno J., Gardon J., Boussinesq M., Muñoz J., et Krolewiecki A.,
Safety of high-dose ivermectin: a systematic review and meta-analysis,
J. Antimicrob. Chemother., janv. 2020. doi: 10.1093/jac/dkz524.

Barraud O., Robert A., Laval L., Ruimy R., Morquin D., Boyer L., et Lamy B.,
It takes two to tango: two Aeromonas isolates combine virulence and multidrug resistance in flap infection following leech therapy,
Clin. Microbiol. Infect., janv. 2020. doi: 10.1016/j.cmi.2019.12.021

Yakhelef N., Audibert M., Ferlazzo G., Sitienei J., Wanjala S., Varaine F., Bonnet M., et Huerga H.,
Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis,
PLoS ONE, vol. 15, no 1, p. e0227138, 2020. doi: 10.1371/journal.pone.0227138.

Atwine D., Baudin E., Gelé T., Muyindike W., Mworozi K., Kyohairwe R., Kananura K., Orikiriza P., Nyehangane D., K T Nanjebe D., Furlan V., Verstuyft C., Barrail-Tran A., Taburet A.-M., Bonnet M., et ANRS 12292 Rifavirenz study group,
Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial,
J. Antimicrob. Chemother., janv. 2020. doi: 10.1093/jac/dkz557.

Ayouba A. et Peeters M.,
Reply to Zhang et al,
J. Infect. Dis., févr. 2020. doi: 10.1093/infdis/jiaa041.

Bonnet M.,
Xpert MTB/RIF Ultra: what is the real impact?,
Lancet Respir Med, févr. 2020. doi: 10.1016/S2213-2600(20)30050-3.